Copyright Lobe Science 2021. All rights reserved.

Benjamin Kelmendi, MD

Scientific ADVISOR

Benjamin is a psychiatrist and an Associate Professor in the Department of Psychiatry at the Yale University School of Medicine. His primary clinical expertise is in PTSD, Depression, OCD, and the endocannabinoid system. He is the co-founder of the Yale Psychedelic Science Group. He leads a research program focused on the therapeutic potential of psychedelic medicines, across a range of psychiatric diagnoses. He is currently investigating the effects of psilocybin on the neurocircuitry implicated in the development, maintenance, and treatment of patients with OCD. He is also exploring the effects of MDMA on brain activation and neural network organization in PTSD to understand the relationship between MDMA-induced neural changes and the acute cognitive and behavioral effects of the drug.

Ilan Hayman

ADVISOR

Ilan has played a pivotal role in the General Management of healthcare businesses including a private cosmetic surgery chain and the commercialisation of a breakthrough skincare range. He successfully led the development of these products from concept through to production commercialisation. Most recently Ilan oversaw a group of national medical centers.  His career into operations management was triggered by his valuable experience as part of the Risk and Controls Solutions practice at PricewaterhouseCoopers (PwC). Specifically, Ilan’s passion is assisting the medical fraternity in their practice management and business administration functions. Ilan’s ambition is to work in a role that utilises his analysis expertise enriched by his exposure to the commercial side of business. Ilan has a passion for assisting community organisations and sits on several boards of not for profit organisations. He also holds Bronze and Silver Duke of Edinburgh awards and brings along a unique set of community and industry related experience.

Bart Oates

ADVISOR

Bart Oates Esq. is a three-time Superbowl Champion, who graduated magna cum laude with a Juris Doctor degree from Seton Hall during his off season. Prior to his NFL career, he earned a BS in Accounting from the Marriott School of Business at BYU and was inducted into their athletic Hall of Fame in 1992. Bart was selected to five Pro Bowls during his NFL career and to the UPI All-NFC team three times. Bart is now the President of the NFL Alumni Association which offers former players a diverse package of medical, business, and legal services to help keep them and their families healthy, productive, and connected to their former teammates.

Michael Petter

DIRECTOR

Michael is an accomplished leader and entrepreneur in the psychedelics and cannabis industry, co-founding and acting as a director of several companies that successfully completed M&A transactions. He holds a Bachelors in Computer Science from London University, is a Chartered Engineer and private pilot. Since January 2009, he has been the Managing Director of Eyvo eProcurement Solutions, a US-based private company that is a leading eProcurement provider in the SaaS space. He also runs a business mentoring program that assists businesses and individuals with change management. Mike was co-founder and director of Eleusian Biosciences Corp., which the Company acquired in July 2020. He also co-founded and was a director of Tassili Life Sciences Corp. which was acquired by CSE-listed Champignon Brands Inc. in March 2020. Mr. Petter has independent board experience being chairman of a compensation committee and as a member of an audit committee. His executive advisory skills focus on providing guidance on strategy, operations, finance and logistics.

Leighton Bocking

Director

Leighton has been working in the capital markets for over 15 years. His primary role has been as an independent corporate development consultant in addition to holding various directorship positions. Leighton has been particularly focused on financing and structuring companies. An active investor, he started in the industry at Canaccord before moving to the public company side of the business.

Dr. Mark A. Geyer Ph.D

Scientific Advisor

Dr. Geyer is Distinguished Professor of Psychiatry and Neurosciences Emeritus at the University of California San Diego (UCSD) and directs the Neuropsychopharmacology Unit of the VISN 22 Veterans Administration Mental Illness Research, Clinical, and Education Center. He is respected internationally for his research on the psychophysiology, neurobiology, and pharmacotherapy of schizophrenia and bipolar disorder. Dr. Geyer’s broad experience as a researcher, grant reviewer, journal editor, and teacher lends invaluable scientific and professional expertise to several organizations, as he provides leadership to develop strong programs in the behavioral psychopharmacology and clinical applications of psychedelic agents.

Maghsoud Dariani

Chief Science Officer

Prior to leading science and technology efforts at LOBE, Dariani was President of Focus Pharmaceuticals, Inc., where he managed the development and approval of drug products, achieving one FDA approval and bringing another to the clinical evaluation stage, then successfully negotiated the sale of the company in February 2003. Prior to Focus, Maghsoud was Vice President of the chiral pharmaceutical business unit at Celgene Corporation. During his twelve years at Celgene, he was responsible for the successful development and FDA approval of the chirally pure versions of Ritalin, which are currently marketed by Novartis under the Focalin and Focalin XR trade names.

Brian Zasitko

Chief Financial Officer

Brian has over 13 years of experience across a variety of private and public sector companies in the cannabis, agriculture, manufacturing, and utility industries. He has extensive experience in financial reporting and corporate governance, as well as in the capital markets. Previously, Brian was a manager at Ernst & Young LLP, where he obtained his CPA, CA designation.

Jonathan Gilbert

EXECUTIVE CHAIRMAN

Most recently, Jonathan was the founder and CEO at Tassili LifeSciences, Corp., a biotech firm conducting research utilizing Psilocybin. He was also the founder and CEO of Scythian Biosciences, Inc. from December of 2014 through May of 2018. Scythian was a publicly traded research and development company in Canada focusing on the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination, as well as strategic investments and partnerships across cultivation, distribution and retail of legal Cannabis.

Philip J. Young

CEO & DIRECTOR

Mr. Young is an analytical and results driven life sciences executive who has successfully managed public and private companies through product development, international growth, commercialization and M&A transactions. He has served as a Director and Chief Executive Officer for public companies for the past 20 years where has had created significant shareholder value, built integrated scientific, manufacturing and commercial operations, directed successful M&A transactions and was responsible for generating more the $900M through acquisitions and equity financings. Mr. Young started his management career in the biopharmaceutical industry at Genentech Inc. where he was responsible for their cardiovascular and endocrine product launches sales and marketing.